

# Sherif E Emam

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/761721/sherif-e-emam-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

18  
papers

129  
citations

6  
h-index

11  
g-index

18  
ext. papers

225  
ext. citations

4.7  
avg, IF

2.53  
L-index

#	Paper	IF	Citations
18	A mouse model for studying the effect of blood anti-PEG IgMs levels on the in vivo fate of PEGylated liposomes.. <i>International Journal of Pharmaceutics</i> , <b>2022</b> , 121539	6.5	0
17	Using Bio-Layer Interferometry to Evaluate Anti-PEG Antibody-Mediated Complement Activation.. <i>Biological and Pharmaceutical Bulletin</i> , <b>2022</b> , 45, 129-135	2.3	
16	Electrospun Nanofibers Revisited: An Update on the Emerging Applications in Nanomedicine.. <i>Materials</i> , <b>2022</b> , 15,	3.5	2
15	Characterization of undescribed melanoma inhibitors from <i>Euphorbia mauritanica</i> L. cultivated in Egypt targeting BRAF and MEK 1 kinases via in-silico study and ADME prediction.. <i>Phytochemistry</i> , <b>2022</b> , 113154	4	0
14	Exosomes in Alzheimer's Disease: From Being Pathological Players to Potential Diagnostics and Therapeutics. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	10
13	Incorporating Gangliosides into PEGylated Cationic Liposomes that Complexed DNA Attenuates Anti-PEG Antibody Production but Not Anti-DNA Antibody Production in Mice. <i>Molecular Pharmaceutics</i> , <b>2021</b> , 18, 2406-2415	5.6	1
12	Increasing Tumor Extracellular pH by an Oral Alkalinizing Agent Improves Antitumor Responses of Anti-PD-1 Antibody: Implication of Relationships between Serum Bicarbonate Concentrations, Urinary pH, and Therapeutic Outcomes. <i>Biological and Pharmaceutical Bulletin</i> , <b>2021</b> , 44, 844-852	2.3	0
11	Anti-PEG IgM production and accelerated blood clearance phenomenon after the administration of PEGylated exosomes in mice. <i>Journal of Controlled Release</i> , <b>2021</b> , 334, 327-334	11.7	4
10	An updated review of mesoporous carbon as a novel drug delivery system. <i>Drug Development and Industrial Pharmacy</i> , <b>2021</b> , 1-9	3.6	5
9	Efficient construction of the hexacyclic ring core of palauamine: the p concept for proceeding with unfavorable equilibrium reactions. <i>Chemical Science</i> , <b>2021</b> , 12, 12201-12210	9.4	1
8	Pegfilgrastim (PEG-G-CSF) induces anti-PEG IgM in a dose dependent manner and causes the accelerated blood clearance (ABC) phenomenon upon repeated administration in mice. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , <b>2020</b> , 152, 56-62	5.7	6
7	Impact of Pre-Existing or Induced Anti-PEG IgM on the Pharmacokinetics of Peginterferon Alfa-2a (Pegasys) in Mice. <i>Molecular Pharmaceutics</i> , <b>2020</b> , 17, 2964-2970	5.6	4
6	Pegfilgrastim (PEG-G-CSF) Induces Anti-polyethylene Glycol (PEG) IgM via a T Cell-Dependent Mechanism. <i>Biological and Pharmaceutical Bulletin</i> , <b>2020</b> , 43, 1393-1397	2.3	4
5	Cancer cell-type tropism is one of crucial determinants for the efficient systemic delivery of cancer cell-derived exosomes to tumor tissues. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , <b>2019</b> , 145, 27-34	5.7	21
4	A Novel Strategy to Increase the Yield of Exosomes (Extracellular Vesicles) for an Expansion of Basic Research. <i>Biological and Pharmaceutical Bulletin</i> , <b>2018</b> , 41, 733-742	2.3	35
3	Liposome co-incubation with cancer cells secreted exosomes (extracellular vesicles) with different proteins expressions and different uptake pathways. <i>Scientific Reports</i> , <b>2018</b> , 8, 14493	4.9	20
2	Doxorubicin Expands in Vivo Secretion of Circulating Exosome in Mice. <i>Biological and Pharmaceutical Bulletin</i> , <b>2018</b> , 41, 1078-1083	2.3	8

1 Pediatric suppositories of sulpiride solid dispersion for treatment of Tourette syndrome: in vitro and in vivo investigations. *AAPS PharmSciTech*, **2015**, 16, 645-55 3.9 8